DE05011213T1 - Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin - Google Patents

Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin Download PDF

Info

Publication number
DE05011213T1
DE05011213T1 DE05011213T DE05011213T DE05011213T1 DE 05011213 T1 DE05011213 T1 DE 05011213T1 DE 05011213 T DE05011213 T DE 05011213T DE 05011213 T DE05011213 T DE 05011213T DE 05011213 T1 DE05011213 T1 DE 05011213T1
Authority
DE
Germany
Prior art keywords
dosing interval
beginning
buprenorphine
hours
release rate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE05011213T
Other languages
English (en)
Inventor
F. Robert Greenwich REDER
D. Paul Wilton GOLDENHEIM
F. Robert Weston KAIKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26715643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE05011213(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of DE05011213T1 publication Critical patent/DE05011213T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Verwendung einer Polymermatrixschicht, umfassend Buprenorphin oder ein pharmazeutisch akzeptables Salz davon, und eine Stützschicht, die aus einem pharmazeutisch akzeptablen Material gefertigt ist, und welche für Buprenorphin undurchlässig ist, bei der Herstellung eines transdermalen Abgabesystems für Buprenorphin, welches für die Behandlung von Schmerzen in einem menschlichen Patienten für ein Dosierintervall von mindestens vier Tagen wirksam ist, wobei das transdermale Abgabesystem durch Aufbringen des transdermalen Abgabesystems auf die Haut eines Patienten eine Freisetzungsrate an Buprenorphin über ungefähr ein 72 Stunden Dosierintervall bereitstellt, so dass eine maximale Plasmakonzentration von 20 pg/ml bis 850 pg/ml erreicht wird und die transdermale Abgabeeinheit, wenn sie auf der Haut des Patienten für ein zusätzliches 24 Stunden Intervall beibehalten wird, Plasmakonzentrationen an Buprenorphin in den Patienten oberhalb der minimalen wirksamen Konzentrationen an Buprenorphin bereitstellt, so dass die Patienten während dieses zusätzlichen Dosierintervalls weiterhin wirksames Schmerzmanagement erfahren.

Claims (8)

  1. Verwendung einer Polymermatrixschicht, umfassend Buprenorphin oder ein pharmazeutisch akzeptables Salz davon, und eine Stützschicht, die aus einem pharmazeutisch akzeptablen Material gefertigt ist, und welche für Buprenorphin undurchlässig ist, bei der Herstellung eines transdermalen Abgabesystems für Buprenorphin, welches für die Behandlung von Schmerzen in einem menschlichen Patienten für ein Dosierintervall von mindestens vier Tagen wirksam ist, wobei das transdermale Abgabesystem durch Aufbringen des transdermalen Abgabesystems auf die Haut eines Patienten eine Freisetzungsrate an Buprenorphin über ungefähr ein 72 Stunden Dosierintervall bereitstellt, so dass eine maximale Plasmakonzentration von 20 pg/ml bis 850 pg/ml erreicht wird und die transdermale Abgabeeinheit, wenn sie auf der Haut des Patienten für ein zusätzliches 24 Stunden Intervall beibehalten wird, Plasmakonzentrationen an Buprenorphin in den Patienten oberhalb der minimalen wirksamen Konzentrationen an Buprenorphin bereitstellt, so dass die Patienten während dieses zusätzlichen Dosierintervalls weiterhin wirksames Schmerzmanagement erfahren.
  2. Verwendung eines transdermalen Abgabesystems für Buprenorphin, das vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls eine mittlere Freisetzungsrate von 3 μg/Std. bis 86 μg/Std. an Buprenorphin bereitstellt und, basierend auf einem transdermalen Abgabesystem mit 10 mg Buprenorphin, von 72 Stunden nach dem Beginn des Dosierintervalls bis mindestens 96 Stunden nach dem Beginn des Dosierintervalls eine mittlere Freisetzungsrate von 0,3 μg/Std. bis 9 μg/Std. bereitstellt, bei der Herstellung eines transdermalen Abgabesystems für Buprenorphin, das für die Behandlung von Schmerzen bei einem menschlichen Patienten für ein Dosierintervall von mindestens vier Tagen wirksam ist, wobei das transdermale Abgabesystem durch Aufbringung des transdermalen Abgabesystems auf die Haut eines Patienten über ein 72 Stunden Dosierintervall eine maximale Plasmakonzentration von 20 pg/ml bis 850 pg/ml bereitstellt, und, wenn es für ein zusätzliches 24 Stundenintervall auf der Haut des Patienten beibehalten wird, Plasmakonzentrationen an Buprenorphin oberhalb den minimalen wirksamen Konzentrationen an Buprenorphin bereitstellt, so dass die Patienten während dieses zusätzlichen Dosierintervalls weiterhin wirksames ein Schmerzmanagement erfahren.
  3. Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 3 μg/Std. bis 5 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 0,3 μg/Std. bis 0,6 μg/Std. von 72 Stunden nach Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
  4. Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 6 μg/Std. bis 11 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 0,7 μg/Std. bis 1 μg/Std. bis 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
  5. Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 13 μg/Std. bis 21 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 1 μg/Std. bis 2 μg/Std. von 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
  6. Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 26 μg/Std. bis 43 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 3 μg/Std. bis 4 μg/Std. von 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
  7. Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 39 μg/Std. bis 64 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 4 μg/Std. bis 7 μg/Std. von 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
  8. Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 51 μg/Std. bis 86 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 5 μg/Std. bis 9 μg/Std. von 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
DE05011213T 1997-02-24 1998-02-24 Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin Pending DE05011213T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3891997P 1997-02-24 1997-02-24
US38919P 1997-02-24
US939068 1997-09-29
US08/939,068 US5968547A (en) 1997-02-24 1997-09-29 Method of providing sustained analgesia with buprenorphine

Publications (1)

Publication Number Publication Date
DE05011213T1 true DE05011213T1 (de) 2007-09-06

Family

ID=26715643

Family Applications (2)

Application Number Title Priority Date Filing Date
DE05011213T Pending DE05011213T1 (de) 1997-02-24 1998-02-24 Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin
DE69835584T Expired - Lifetime DE69835584T2 (de) 1997-02-24 1998-02-24 Verzögerte analgesie erreicht mit transdermaler verabreichung von buprenorphin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69835584T Expired - Lifetime DE69835584T2 (de) 1997-02-24 1998-02-24 Verzögerte analgesie erreicht mit transdermaler verabreichung von buprenorphin

Country Status (22)

Country Link
US (15) US5968547A (de)
EP (9) EP2305194B1 (de)
JP (1) JP2000511936A (de)
KR (1) KR100703101B1 (de)
CN (2) CN1252705A (de)
AT (3) ATE556682T1 (de)
AU (2) AU2004218685B2 (de)
BR (1) BR9815439A (de)
CA (1) CA2276170C (de)
CZ (2) CZ299414B6 (de)
DE (2) DE05011213T1 (de)
DK (4) DK0964677T3 (de)
ES (4) ES2423925T3 (de)
HK (3) HK1096847A1 (de)
HU (3) HUP1500370D0 (de)
IL (4) IL131561A0 (de)
NO (11) NO322515B1 (de)
NZ (1) NZ337386A (de)
PL (1) PL196086B1 (de)
PT (4) PT1570823E (de)
SI (3) SI1570823T1 (de)
WO (1) WO1998036728A2 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265353A1 (en) * 1995-07-28 2004-12-30 Zars, Inc. Systems and methods for treating panic attacks
US20020114827A1 (en) * 1995-07-28 2002-08-22 Jie Zhang Methods and apparatus for improved administration of analgesics
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DK1041987T3 (da) 1997-12-22 2006-08-21 Euro Celtique Sa Oral farmaceutisk doseringsform omfattende en kombination af en opioid-agonist og naltrexon
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
RS50407B (sr) 2000-02-08 2009-12-31 Euro-Celtique S.A., Oralne formulacije opijatnog agonista otporne na mehaničke,termičke i/ili hemijske promene fizičkih osobina doznog oblika
DK1255547T3 (da) 2000-02-08 2008-12-01 Euro Celtique Sa Kontrolleret-frigivelsessammensætninger indeholdende opioid-agonist og antagonist
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1280485A4 (de) * 2000-02-29 2006-11-29 Zars Inc Verbessertes transdermales medizinpflaster
KR100452972B1 (ko) * 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
AU2001262683A1 (en) * 2000-06-02 2001-12-17 Teijin Limited Buprenorphine-containing patch
GB0021317D0 (en) * 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
ES2309107T3 (es) * 2000-10-23 2008-12-16 Euro-Celtique S.A. Dispositivo y metodos transdermicos para felodipina.
DK1335689T3 (da) 2000-10-23 2010-06-14 Euro Celtique Sa System til transdermal indgivelse af loratadin og anvendelse deraf
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
JP4908726B2 (ja) * 2001-02-16 2012-04-04 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ブプレノルフィンを尿失禁の治療に使用する方法
WO2002083135A2 (en) * 2001-02-16 2002-10-24 Grünenthal GmbH Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
NZ528241A (en) * 2001-03-02 2004-08-27 Euro Celtique S N-but-3-enyl norbuprenorphine and methods of use
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
WO2003002100A1 (en) * 2001-06-26 2003-01-09 Farrell John J Tamper-proof narcotic delivery system
CA2454328C (en) 2001-07-18 2008-03-18 Christopher D. Breder Pharmaceutical combinations of oxycodone and naloxone
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
MXPA04001210A (es) 2001-08-06 2004-07-08 Euro Celtique Sa Formulaciones de agonista opioide con antagonista liberable y aislado.
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US7645813B2 (en) * 2001-08-10 2010-01-12 Cosmed Pharmaceutical Co., Ltd. Pressure-sensitive adhesive for the skin and tapes or sheets for the skin made by using the same
JP2005516926A (ja) * 2001-12-17 2005-06-09 アリックス セラピューティクス 鎮痛薬の送達システム及び使用方法
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
DK1485051T3 (da) * 2002-03-20 2008-09-08 Euro Celtique Sa Fremgangsmåde til indgivelse af buprenorphin til behandling af depression
CN102813654A (zh) 2002-04-05 2012-12-12 欧洲凯尔蒂克公司 含有羟氢可待酮和烯丙羟吗啡酮的药物制剂
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
JP4668611B2 (ja) * 2002-05-31 2011-04-13 タイタン ファーマシューティカルズ インコーポレイテッド ブプレノルフィンの持続放出のための埋め込み型ポリマー製装置
CA2488915C (en) 2002-06-10 2011-10-04 Euro-Celtique S.A. Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
DE50307717D1 (de) * 2002-08-09 2007-08-30 Gruenenthal Gmbh Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin
AU2003268144A1 (en) * 2002-08-20 2004-03-11 Euro-Celtique, S.A. Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
PT1551372T (pt) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
AU2003285934A1 (en) * 2002-10-25 2004-05-25 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
ES2310262T3 (es) * 2002-12-13 2009-01-01 Euro-Celtique S.A. Regimen de dosificacion de bruprenorfina transdermica para analgesia.
EP1913938A1 (de) 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermales Dosierungsschema für Buprenorphin zur Schmerzstillung
WO2004054554A1 (en) * 2002-12-13 2004-07-01 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
CN1777426A (zh) 2003-03-31 2006-05-24 泰坦医药品公司 用于持续释放多巴胺受体激动剂的可植入聚合物装置
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US7879357B2 (en) * 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
ME00276B (me) 2003-04-30 2011-05-10 Purdue Pharma Lp Transdermalni dozni oblik otporan na promjene koje sadrže komponentu aktivnog sredstva i komponentu suprotnog sredstva na mjestu koji je ispod sloja aktivnog sredstva
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
WO2004103317A2 (en) * 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
KR20080011248A (ko) * 2003-07-25 2008-01-31 유로-셀띠끄 소시에떼 아노님 수술후 통증의 수술전 치료
KR100829492B1 (ko) 2003-07-25 2008-05-19 유로-셀띠끄 소시에떼 아노님 의존성 금단의 치료
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
PT1718258E (pt) 2004-02-23 2009-06-16 Euro Celtique Sa Dispositivo de administração transdérmica de opióides com resistência ao abuso
US7220842B2 (en) 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
EP1765292B1 (de) 2004-06-12 2017-10-04 Collegium Pharmaceutical, Inc. Gegen missbrauch gesicherte arzneimittelformulierungen
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
EP1743638A1 (de) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmazeutische Formulierungen von substituierten Pyrazolinderivaten
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252329B2 (en) * 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
CA2935569A1 (en) * 2006-04-13 2007-10-25 Teva Pharmaceuticals International Gmbh Transdermal methods and systems for the delivery of anti-migraine compounds
EP2526932B1 (de) 2006-06-19 2017-06-07 Alpharma Pharmaceuticals LLC Pharmazeutische Zusammensetzung
EP1897543A1 (de) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine-Waffel zur Substitutionstherapie
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
DE102006054732B4 (de) 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
US20110008431A1 (en) * 2007-04-02 2011-01-13 Toyo Boseki Kabushiki Kaisha Therapeutic tablet for postherpetic neuralgia and method of treating postherpetic neuralgia
EP3269346A1 (de) * 2007-08-07 2018-01-17 Acelrx Pharmaceuticals, Inc. Vorrichtung zur oralen medikamentengabe
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20110097395A1 (en) * 2008-03-08 2011-04-28 Najib Babul Oral Pharmaceutical Compositions of Buprenorphine and Method of Use
AU2009271271A1 (en) * 2008-06-23 2010-01-21 Biodelivery Sciences International, Inc. Multidirectional mucosal delivery devices and methods of use
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2010107761A1 (en) 2009-03-18 2010-09-23 Acelrx Pharmaceuticals, Inc. Improved storage and dispensing devices for administration of oral transmucosal dosage forms
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US20110037455A1 (en) * 2009-08-17 2011-02-17 Oren Navot System for measuring electrical power
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
EP2611445B1 (de) * 2010-09-03 2018-08-15 Zoetis Belgium S.A. Hochdosierte buprenorphine zusammensetzungen und verwendung als analgetika
WO2012048455A1 (zh) * 2010-10-12 2012-04-19 武汉大学 一种抗病毒透皮吸收贴片及其制备方法
DK2640389T3 (en) * 2010-11-17 2015-03-09 Hexal Ag Transdermal therapeutic system comprising buprenorphine
DE102011076653A1 (de) 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
WO2013042054A1 (en) * 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
MX352795B (es) * 2011-12-12 2017-12-07 Lts Lohmann Therapie Systeme Ag Sistema de administracion transdermica que comprende buprenorfina.
EA201992762A1 (ru) * 2011-12-21 2020-07-31 Байоделивери Сайенсиз Интернэшнл, Инк. Трансмукозальные устройства для доставки лекарств для применения при облегчении хронической боли
US20130211351A1 (en) * 2012-01-31 2013-08-15 Gruenenthal Gmbh Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
TWI522101B (zh) 2012-04-17 2016-02-21 普渡製藥有限合夥事業 處理由類鴉片引起之不利的藥效動力反應之系統和方法
WO2014031958A1 (en) * 2012-08-24 2014-02-27 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
WO2014105480A1 (en) 2012-12-28 2014-07-03 Teikoku Pharma Usa, Inc. Extended buprenorphine transdermal delivery compositions and methods for using the same
MX362614B (es) 2013-06-04 2019-01-28 Lts Lohmann Therapie Systeme Ag Sistema de liberación transdérmico.
CA2918004C (en) 2013-07-23 2018-11-20 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
DE102014013448A1 (de) 2014-09-16 2016-03-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales Therapeutisches System umfassend Buprenorphin
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
AU2015369710B2 (en) 2014-12-23 2020-09-17 Vertical Pharmaceuticals, Llc Systems, devices and methods for dispensing oral transmucosal dosage forms
US9656441B2 (en) 2015-01-08 2017-05-23 Alfred E. Tiefenbacher ( Gmbh & Co. Kg) Transdermal patch
JP6660399B2 (ja) 2015-03-10 2020-03-11 ローズ テクノロジーズ ブプレノルフィンの酢酸塩及びブプレノルフィンの調製方法
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
WO2019175109A1 (en) * 2018-03-13 2019-09-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
US20210251983A1 (en) * 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Methods of treatment with buprenorphine
CZ37580U1 (cs) 2022-03-02 2023-12-21 RECUTECH s.r.o Teplo-vlhkosměnná deska a entalpický výměník

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4058599A (en) 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
US4262003A (en) * 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4060084A (en) * 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4119713A (en) 1977-02-09 1978-10-10 Sam Carosio Analgesic and anti-inflammatory composition
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
DE3330750A1 (de) * 1983-08-26 1985-03-14 Chemische Werke Hüls AG, 4370 Marl Verfahren zur erzeugung von acetylen und synthese- oder reduktionsgas aus kohle in einem lichtbogenprozess
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4636539A (en) 1984-01-30 1987-01-13 Loctite (Ireland) Limited Instant adhesive composition utilizing calixarene accelerators
US4601893A (en) 1984-02-08 1986-07-22 Pfizer Inc. Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
DE3546830C2 (de) 1984-07-23 1995-07-20 Alza Corp Transdermales Abgabesystem zur Verabreichung von Fentanyl
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4834978A (en) 1984-10-01 1989-05-30 Biotek, Inc. Method of transdermal drug delivery
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4698062A (en) 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
USRE33093E (en) 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
JPS62298530A (ja) 1986-06-16 1987-12-25 Otsuka Pharmaceut Co Ltd 坐薬用医薬組成物
US4938759A (en) 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5091405A (en) * 1987-01-05 1992-02-25 E. I. Du Pont De Nemours And Company Insecticidal pyrazolines
US5171576A (en) 1987-03-09 1992-12-15 Alza Corporation Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
DE3812481A1 (de) * 1987-08-26 1989-03-09 Bayer Ag Wasserhaertende polymerzubereitung
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4983395A (en) * 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4994278A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
US5336210A (en) * 1989-02-28 1994-08-09 Teijin Limited Plaster agent
US5028435A (en) 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DE3939376C1 (de) * 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
EP0432945A1 (de) * 1989-12-12 1991-06-19 Warner-Lambert Company Transdermales Abgabesystem zur Behandlung der Kokain- und Heroinsucht
JP2849937B2 (ja) * 1990-04-18 1999-01-27 日東電工株式会社 医療用貼付剤
KR950005865B1 (ko) * 1990-04-23 1995-06-02 데이진 가부시끼가이샤 첩부제
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
DE4020144A1 (de) * 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen
US5688547A (en) 1990-08-03 1997-11-18 American Cyanamid Company Meal replacement composition and method of weight control
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
CN1036343C (zh) 1990-11-10 1997-11-05 天津市计划生育研究所 新促黄体生成素释放激素拮抗类似物的制备方法
PL166095B1 (pl) 1991-04-03 1995-03-31 Warszawskie Zaklady Farma Sposób wytwarzania N-cyklopropylometylo-7a -[(S)-1-hydroksy-1,2,2-trimetylopropylo] endo-etano-6,7,8,14-tetrahydronororipaviny
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
AU657973B2 (en) 1991-05-07 1995-03-30 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5225440A (en) * 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
US5229130A (en) 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5272149A (en) 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
WO1993023019A1 (en) 1992-05-11 1993-11-25 Sri International Transdermal drug delivery systems and related compositions and methods of use
DE69326848T2 (de) 1992-05-13 2000-01-27 Alza Corp Oxybutynin zur transdermalen Verabreichung
NZ253409A (en) 1992-06-11 1996-09-25 Theratech Inc Drug delivery system; transdermal/transmucosal system using glycerine to moderate drug delivery
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
DE4237453C1 (de) 1992-11-06 1993-08-19 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
DK0695177T3 (da) * 1993-04-20 1998-09-28 Hexal Ag Plaster indeholdende aktivt stof
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
AU7396294A (en) 1993-06-25 1995-01-24 Alza Corporation Incorporating poly-n-vinyl amide in a transdermal system
WO1995005138A1 (en) 1993-08-16 1995-02-23 Cygnus Therapeutic Systems Contact adhesive extends wear time on skin
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
WO1995019991A1 (en) 1994-01-20 1995-07-27 Akzo Nobel N.V. New composition of glycoprotein isoforms having follicle stimulating activity
JPH07206710A (ja) * 1994-01-21 1995-08-08 Nitto Denko Corp 経皮投薬用テープ製剤
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
JP2819236B2 (ja) * 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5468457A (en) 1994-12-22 1995-11-21 Osram Sylvania Inc. Method of making tungsten-copper composite oxides
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
AU6657396A (en) * 1995-07-28 1997-02-26 Novartis Ag Transdermal system
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
FR2739731B1 (fr) 1995-10-09 1998-01-02 Axon Cable Sa Procede de raccordement de micro-cables coaxiaux aux pistes d'un circuit imprime
DE19642043A1 (de) * 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
US5792740A (en) 1996-03-08 1998-08-11 Firmenich Sa Fragrant macrocyclic lactones
DK0889723T3 (da) 1996-03-25 2002-09-23 Lohmann Therapie Syst Lts Transdermalt terapeutisk system med ringe tykkelse af administreringsareal og stor fleksibilitet samt fremgangsmåde til fremstilling heraf
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US6271240B1 (en) 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
JPH1036265A (ja) 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
EP0821957A3 (de) 1996-08-01 1998-04-22 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von Drogenmissbrauch
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
AT405158B (de) * 1996-12-04 1999-06-25 Steyr Daimler Puch Ag Verfahren zur selbsttätigen steuerung der sperrkupplungen eines allradgetriebenen fahrzeuges und fahrzeug mit knicklenkung und sperrbaren differentialen
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
DE19652188C2 (de) * 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
BR9807828A (pt) 1997-02-07 2000-03-08 Theratech Inc Composições e método para a suplementação de testosterona em mulheres com sintomas de deficiência de testosterona
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
WO1998048811A1 (en) 1997-04-30 1998-11-05 Human Pheromone Sciences, Inc. Method of fixing fragrances in fragrance composition and other compositions
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US5900420A (en) 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
GB2328443B (en) 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
DE19738855C2 (de) 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US7011843B2 (en) 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
HUP0100310A3 (en) 1997-12-22 2002-11-28 Euro Celtique Sa A method of preventing abuse of opioid dosage forms
WO1999045906A1 (en) 1998-03-09 1999-09-16 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
WO1999048546A1 (en) 1998-03-23 1999-09-30 Elan Corporation, Plc Drug delivery device
WO1999055312A2 (en) 1998-04-29 1999-11-04 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
DE19840758A1 (de) 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Systemische Therapie von Schmerz- und depressiver Befindlichkeit
KR100383252B1 (ko) 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
IT1305303B1 (it) 1999-03-10 2001-05-04 Farmigea Spa Uso dell'olio essenziale di niaouli come promotore per la permeazionetransdermica.
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6554851B1 (en) 1999-05-07 2003-04-29 Scimed Life Systems, Inc. Methods of sealing an injection site
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) * 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP2283865A1 (de) 2000-08-30 2011-02-16 Unimed Pharmaceuticals, LLC Verfahren zur Erhöhung des Testosteron-Spiegels und verwandter Steroidverbindungen bei Frauen
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
NZ528241A (en) 2001-03-02 2004-08-27 Euro Celtique S N-but-3-enyl norbuprenorphine and methods of use
ATE468856T1 (de) 2001-03-23 2010-06-15 Einstein Coll Med Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid
EP2266719B1 (de) 2001-04-23 2016-06-08 Euro-Celtique S.A. Entsorgungssystem für transdermale Dosierformen
SI2062573T1 (sl) * 2001-05-01 2012-02-29 Euro Celtique Sa Proti zlorabi odporni transdermalni sistemi, ki vsebujejo opioid
ES2340149T3 (es) 2001-05-22 2010-05-31 Euro-Celtique S.A. Contenedor y metodo para dispensar formas de dosificacion transdermicas.
RU2003135208A (ru) 2001-06-04 2005-05-10 Квинетик Лимитед (Gb) Способ формирования рисунка
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US20030114475A1 (en) 2001-10-31 2003-06-19 Addiction Therapies, Inc. Methods for the treatment of addiction
DK1485051T3 (da) * 2002-03-20 2008-09-08 Euro Celtique Sa Fremgangsmåde til indgivelse af buprenorphin til behandling af depression
ATE382050T1 (de) 2002-11-25 2008-01-15 Chi Mei Foundation Medical Ct Buprenorphinesterderivate, verfahren zu ihrer herstellung, und langwirksame analgetische arzneimittel
WO2004054554A1 (en) * 2002-12-13 2004-07-01 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
ES2310262T3 (es) 2002-12-13 2009-01-01 Euro-Celtique S.A. Regimen de dosificacion de bruprenorfina transdermica para analgesia.
WO2004103317A2 (en) * 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
KR100829492B1 (ko) 2003-07-25 2008-05-19 유로-셀띠끄 소시에떼 아노님 의존성 금단의 치료
KR20080011248A (ko) 2003-07-25 2008-01-31 유로-셀띠끄 소시에떼 아노님 수술후 통증의 수술전 치료
JP2007502839A (ja) 2003-08-21 2007-02-15 トランソラル ファーマシューティカルズ，インコーポレイティド 口腔粘膜を介して５−ｈｔアゴニストを運搬するための組成物及びその使用方法
WO2006119286A1 (en) 2005-05-03 2006-11-09 Innozen, Inc. Edible film for transmucosal delivery of nutritional supplements
JP5586151B2 (ja) 2005-12-13 2014-09-10 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド 乱用抵抗性経粘膜薬剤送達デバイス
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
CA2654661C (en) 2006-06-26 2012-10-23 Amgen Inc. Compositions comprising modified lcat and use thereof for treating atherosclerosis
WO2008011194A2 (en) 2006-07-21 2008-01-24 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
EP1897543A1 (de) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine-Waffel zur Substitutionstherapie
CN105168186A (zh) 2006-10-02 2015-12-23 Apr应用制药研究股份公司 非粘膜粘着性膜剂型
EP2069794A1 (de) 2006-10-03 2009-06-17 University of Southern California Grp78 als mittel zur vorhersage der ansprechbarkeit auf therapeutika
GB2447016A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
WO2008115811A2 (en) 2007-03-16 2008-09-25 Endo Pharmaceuticals, Inc. Transdermal delivery form disposal systems and methods
AU2009271271A1 (en) 2008-06-23 2010-01-21 Biodelivery Sciences International, Inc. Multidirectional mucosal delivery devices and methods of use
DK2640389T3 (en) 2010-11-17 2015-03-09 Hexal Ag Transdermal therapeutic system comprising buprenorphine

Also Published As

Publication number Publication date
NO20064395L (no) 1999-10-22
EP2305191A1 (de) 2011-04-06
HU230608B1 (hu) 2017-03-28
NO337094B1 (no) 2016-01-18
NO20074292L (no) 1999-10-22
US9642850B2 (en) 2017-05-09
PT1731152E (pt) 2013-07-31
US20010002259A1 (en) 2001-05-31
AU743071B2 (en) 2002-01-17
ES2387752T3 (es) 2012-10-01
NO20101190L (no) 1999-10-22
DK2305194T3 (da) 2012-08-13
NO2017011I1 (no) 2017-04-04
EP1731152A2 (de) 2006-12-13
EP1731152B1 (de) 2013-05-01
US5968547A (en) 1999-10-19
US20140073663A1 (en) 2014-03-13
DK1570823T3 (da) 2012-02-20
EP2301494A1 (de) 2011-03-30
CN1827107A (zh) 2006-09-06
NO340067B1 (no) 2017-03-06
NO20111441L (no) 1999-10-22
USRE41408E1 (en) 2010-06-29
HUP1500370D0 (hu) 2000-12-28
CN1252705A (zh) 2000-05-10
EP1570823A2 (de) 2005-09-07
NO994087D0 (no) 1999-08-24
ATE336212T1 (de) 2006-09-15
HK1103621A1 (en) 2007-12-28
NO329838B1 (no) 2011-01-10
HK1096847A1 (en) 2007-06-15
HK1153377A1 (en) 2012-03-30
HUP1200599A2 (en) 2000-12-28
PT1570823E (pt) 2012-03-02
WO1998036728A3 (en) 1998-12-10
EP0964677B1 (de) 2006-08-16
IL131561A (en) 2010-05-31
CA2276170C (en) 2007-12-04
US6344212B2 (en) 2002-02-05
PT2305194E (pt) 2012-08-14
HUP0002342A3 (en) 2001-04-28
CA2276170A1 (en) 1998-08-27
EP1570823B1 (de) 2011-12-28
NO20120563L (no) 1999-10-22
SI0964677T1 (sl) 2006-12-31
US20130197020A1 (en) 2013-08-01
ES2271988T3 (es) 2007-04-16
EP2305193A1 (de) 2011-04-06
US20160220559A1 (en) 2016-08-04
EP1731152A3 (de) 2007-11-14
NO332248B1 (no) 2012-08-06
NO333139B1 (no) 2013-03-11
CZ2015477A3 (cs) 2015-10-21
US20110288112A1 (en) 2011-11-24
EP0964677A4 (de) 2002-12-18
EP2305194B1 (de) 2012-05-09
DE69835584D1 (de) 2006-09-28
NZ337386A (en) 2001-06-29
ATE538765T1 (de) 2012-01-15
ES2380023T3 (es) 2012-05-07
NO20131533L (no) 1999-10-22
DE69835584T2 (de) 2007-08-16
DK1731152T3 (da) 2013-07-22
NO333374B1 (no) 2013-05-13
AU2004218685B2 (en) 2009-01-22
NO2016013I1 (no) 2016-07-18
JP2000511936A (ja) 2000-09-12
HU230374B1 (hu) 2016-03-29
IL131561A0 (en) 2001-01-28
NO334290B1 (no) 2014-01-27
AU2004218685A1 (en) 2004-11-04
EP1570823A3 (de) 2006-01-18
AU6184198A (en) 1998-09-09
NO20151450A1 (no) 1999-10-22
US6231886B1 (en) 2001-05-15
US20170056393A1 (en) 2017-03-02
PL196086B1 (pl) 2007-12-31
PL335306A1 (en) 2000-04-10
IL207067A (en) 2011-12-29
AU2925402A (en) 2002-05-16
USRE41489E1 (en) 2010-08-10
US20030198675A1 (en) 2003-10-23
USRE41571E1 (en) 2010-08-24
EP2301493A1 (de) 2011-03-30
KR20000075648A (ko) 2000-12-26
IL201437A (en) 2010-12-30
HUP0002342A2 (hu) 2000-12-28
CZ299414B6 (cs) 2008-07-16
SI2305194T1 (sl) 2012-10-30
US20150157625A1 (en) 2015-06-11
BR9815439A (pt) 2001-10-16
DK0964677T3 (da) 2006-12-11
AU2008261134B2 (en) 2012-08-02
US20060216340A1 (en) 2006-09-28
CN1827107B (zh) 2010-05-26
US20030091631A1 (en) 2003-05-15
AU2008261134A1 (en) 2009-01-15
EP2305194A1 (de) 2011-04-06
EP0964677A1 (de) 1999-12-22
NO322515B1 (no) 2006-10-16
SI1570823T1 (sl) 2012-03-30
KR100703101B1 (ko) 2007-04-06
EP2305192A1 (de) 2011-04-06
NO20130298L (no) 1999-10-22
AU774779B2 (en) 2004-07-08
ATE556682T1 (de) 2012-05-15
PT964677E (pt) 2006-12-29
ES2423925T3 (es) 2013-09-25
WO1998036728A2 (en) 1998-08-27
NO329734B1 (no) 2010-12-13
CZ300999A3 (cs) 2000-03-15
NO994087L (no) 1999-10-22

Similar Documents

Publication Publication Date Title
DE05011213T1 (de) Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin
DE60100595T2 (de) Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson
AT403122B (de) Therapeutische infusionszubereitung auf basis von aminosäurederivaten
CA2528160A1 (en) Use of 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine for neuronal regeneration and functional recovery
EP2094249A2 (de) Transdermales therapeutisches system zur verabreichung des wirkstoffs buprenorphin
CA2314326A1 (en) Transdermal therapeutic device and method with capsaicin and capsaicin analogs
WO1998008546A8 (en) Therapeutic combinations of rar antagonists and rxr agonists and use thereof
DD296844A5 (de) Verfahren zur herstellung eines pflasters als transdermales therapeutisches system zur verabreichung von wirkstoffen an die haut mit einer abgestuften wirkstoffabgabe sowie verwendung
WO2001013902A2 (de) Wirkstoffkombination enthaltend clonidin und pramipexol
Caraceni et al. Study of the excitability cycle of the blink reflex in Huntington’s chorea
DE19654468C1 (de) Extrem flexibles, dermal oder transdermal wirkendes Pflaster und Verfahren zu seiner Herstellung
EP1978995A1 (de) Verfahren zur behandlung und/oder prophylaxe von multipler sklerose, sowie verwendung von erythropoietin zur herstellung eines arzneimittels zur intermittierenden behandlung und/oder intermittierenden prophylaxe von multipler sklerose
DE19746191C2 (de) Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
DE2006696A1 (de) Pflaster oder Haftverband
DE19850517B4 (de) Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall
Vazquez et al. The effects of sensory stimulation on REM sleep duration
WO2006030030A2 (de) System zur sequentiellen, transdermalen verabreichung von systemisch wirksamen substanzen
Maier Calcitonin
DE60024408T2 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
DE10293600B4 (de) Rezeptoradaptierter Nikotinentzug durch anticholinerge und noradrenerge Blockade
US4259322A (en) Method of treatment of tuberculosis
DE10133576A1 (de) Verwendung von physiologisch aktiven Oligopeptiden zur Stabilisierung des Immunsystems
DE2057174A1 (de) Pharmazeutisches Produkt,insbesondere injizierbares Lokalanaesthetikum
Rezaković et al. Acute and chronic efficacy of 10 mg of nitroglycerin patch in stable angina pectoris
DE4218292C1 (de) Verwendung eines Arzneimittels mit einem Gehalt an Mestanolon und/oder 4-Chlor-1-dehydromethyltestosteron